The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Prialt label, and added the Drugs@FDA approval record. 12
What this version reported
Smaller placebo-controlled trials described in the label found greater short-term pain relief than placebo. The label carries a boxed warning about severe psychiatric symptoms and neurological impairment.↗
Reader guide in this version
Key takeaway
Ziconotide is a lab-made peptide that blocks N-type calcium channels on pain-signalling nerves in the spinal cord, and is the active ingredient in Prialt.1,2 It is FDA-approved for severe chronic pain in adults who need a specialized form of pain treatment and who cannot tolerate, or did not respond to, other treatments such as standard pain medicines or morphine.1 The label carries a boxed warning about severe psychiatric symptoms and neurological impairment, and it is contraindicated in people with a history of psychosis.1
At a glance
- What it is
- An N-type calcium channel blocker. The label states that it binds these channels on pain-sensing nerves in the spinal cord, although its mechanism has not been established in humans.1
- FDA status
- FDA-approved. Drugs@FDA lists Prialt with an original approval date of December 28, 2004. The label carries a boxed warning about neuropsychiatric adverse reactions.1,2
- Human evidence
- Three smaller double-blind, placebo-controlled trials in a total of 457 people with severe chronic pain, described in the label.1
- Evidence strength
- Smaller controlled human trials
What is ziconotide?
Ziconotide is a lab-made peptide used to manage severe chronic pain. It is the active ingredient of Prialt.1
Drugs@FDA lists Prialt, application NDA021060, now held by Esteve.2
How does ziconotide work?
The label states that ziconotide binds to N-type calcium channels on pain-sensing nerves in the spinal cord. Animal results suggest that blocking these channels stops the nerves from passing on pain signals.1
The label states that its mechanism of action has not been established in humans.1
What do human studies show?
The label describes three double-blind, placebo-controlled trials in a total of 457 people with severe chronic pain. Two different schedules for increasing exposure were tested; the faster schedule was less well tolerated and caused substantially more adverse events.1
In the trial that used the slower schedule, pain scores improved by an average of 12% with ziconotide and 5% with placebo after three weeks, a statistically significant difference, according to the label.1
What the evidence base contains
- Controlled human trial Three double-blind, placebo-controlled, multicenter trials in a total of 457 people with severe chronic pain (268 given ziconotide and 189 placebo), described in the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is ziconotide FDA-approved?
Yes. Drugs@FDA lists Prialt, application NDA021060, with an original approval date of December 28, 2004.2
The Prialt label cited here (DailyMed SPL version 6, published July 14, 2025) states that it is indicated for the management of severe chronic pain in adults for whom its specialized form of delivery is warranted and who are intolerant of or refractory to other treatment, such as systemic pain medicines, add-on treatments or morphine.1
The label carries a boxed warning: severe psychiatric symptoms and neurological impairment may occur, all patients should be monitored for cognitive impairment, hallucinations and changes in mood or consciousness, and it is contraindicated in people with a history of psychosis.1
Its other warnings cover meningitis and other infections, reduced consciousness, raised levels of the muscle enzyme creatine kinase, opioid withdrawal when opioids are stopped, and impaired ability to drive.1
What is still unknown?
How ziconotide relieves pain in humans, which the label says has not been established.1
Its long-term benefit: the label’s trials compared ziconotide with placebo in comparisons that lasted up to three weeks.1
Its safety and effectiveness in children, which the label says have not been established.1
Sources for this version
- 1PRIALT (ziconotide acetate) injection, solution · SPL version 6 · published 2025-07-14 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA021060 · original submission status AP · 2004-12-28 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026